Ngā hua rapu kaituhi

1

Lipodystrophy Associated with an HIV-Protease Inhibitor mā Andrew Carr, David A. Cooper

I whakaputaina 1998

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Predictors of disease progression in HIV infection: a review mā Simone E Langford, Jintanat Ananworanich, David A. Cooper

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
3

4-1BB (CD137) controls the clonal expansion and survival of CD8 T cellsin vivo but does not contribute to the development of cytotoxicity mā David A. Cooper, Pratima Bansal‐Pakala, Michael Croft

I whakaputaina 2002

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

<i>In vitro</i> cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV mā Andrew Carr, B. Tindall, Ronald Penny, David A. Cooper

I whakaputaina 1993

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

The histopathology of bronchogenic carcinoma and its relation to growth rate, metastasis, and prognosis mā William A. Weiss, Katharine R. Boucot, David A. Cooper

I whakaputaina 1970

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Rating evidence in treatment guidelines mā Caroline Sabin, David A. Cooper, Simon Collins, Mauro Schechter

I whakaputaina 2013

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

Timing of the Components of the HIV Life Cycle in Productively Infected CD4 <sup>+</sup> T Cells in a Population of HIV-Infected Individuals mā John M. Murray, Anthony D. Kelleher, David A. Cooper

I whakaputaina 2011

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

A new era of antiretroviral drug toxicity mā Alexandra Calmy, Bernard Hirschel, David A. Cooper, Andrew Carr

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy mā Patrick Mallon, J. Philip Miller, David A. Cooper, Andrew Carr

I whakaputaina 2003

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, Ritonavir mā Anthony D. Kelleher, Andrew Carr, John Zaunders, David A. Cooper

I whakaputaina 1996

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Abnormal fat distribution and use of protease inhibitors mā Andrew Carr, Katherine Samaras, Donald J. Chisholm, David A. Cooper

I whakaputaina 1998

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Carta

Tiaki ki tētahi rārangi

I tiakina i:
12

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome mā Andrew Carr, J. Philip Miller, Matthew Law, David A. Cooper

I whakaputaina 2000

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand mā Irene Gramaglia, David A. Cooper, Kent Miner, Byoung S. Kwon, Michael Croft

I whakaputaina 2000

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy mā Andrew Carr, J. Philip Miller, John A. Eisman, David A. Cooper

I whakaputaina 2001

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy mā Gilbert R. Kaufmann, Mark Bloch, John Zaunders, Don Smith, David A. Cooper

I whakaputaina 2000

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? mā Don Smith, Bruce D. Walker, David A. Cooper, Eric Rosenberg, John Kaldor

I whakaputaina 2004

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
17

Iatrogenic Cushing’s Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boos... mā Katherine Samaras, Sarah Pett, Andrew Gowers, Marilyn McMurchie, David A. Cooper

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid mā Philip Cunningham, Danielle G. Smith, Claudette Satchell, David A. Cooper, Bruce J. Brew

I whakaputaina 2000

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy mā Gilbert R. Kaufmann, Mark Bloch, Robert Finlayson, John Zaunders, Don Smith, David A. Cooper

I whakaputaina 2002

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells mā Chantelle Ahlenstiel, Heidi Lim, David A. Cooper, Takaomi Ishida, Anthony D. Kelleher, Kazuo Suzuki

I whakaputaina 2011

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - David A. Cooper

Lipodystrophy Associated with an HIV-Protease Inhibitor mā Andrew Carr, David A. Cooper

Predictors of disease progression in HIV infection: a review mā Simone E Langford, Jintanat Ananworanich, David A. Cooper

4-1BB (CD137) controls the clonal expansion and survival of CD8 T cellsin vivo but does not contribute to the development of cytotoxicity mā David A. Cooper, Pratima Bansal‐Pakala, Michael Croft

<i>In vitro</i> cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV mā Andrew Carr, B. Tindall, Ronald Penny, David A. Cooper

The histopathology of bronchogenic carcinoma and its relation to growth rate, metastasis, and prognosis mā William A. Weiss, Katharine R. Boucot, David A. Cooper

Rating evidence in treatment guidelines mā Caroline Sabin, David A. Cooper, Simon Collins, Mauro Schechter

Timing of the Components of the HIV Life Cycle in Productively Infected CD4 <sup>+</sup> T Cells in a Population of HIV-Infected Individuals mā John M. Murray, Anthony D. Kelleher, David A. Cooper

A new era of antiretroviral drug toxicity mā Alexandra Calmy, Bernard Hirschel, David A. Cooper, Andrew Carr

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy mā Patrick Mallon, J. Philip Miller, David A. Cooper, Andrew Carr

Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, Ritonavir mā Anthony D. Kelleher, Andrew Carr, John Zaunders, David A. Cooper

Abnormal fat distribution and use of protease inhibitors mā Andrew Carr, Katherine Samaras, Donald J. Chisholm, David A. Cooper

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome mā Andrew Carr, J. Philip Miller, Matthew Law, David A. Cooper

Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand mā Irene Gramaglia, David A. Cooper, Kent Miner, Byoung S. Kwon, Michael Croft

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy mā Andrew Carr, J. Philip Miller, John A. Eisman, David A. Cooper

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy mā Gilbert R. Kaufmann, Mark Bloch, John Zaunders, Don Smith, David A. Cooper

Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? mā Don Smith, Bruce D. Walker, David A. Cooper, Eric Rosenberg, John Kaldor

Iatrogenic Cushing’s Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boos... mā Katherine Samaras, Sarah Pett, Andrew Gowers, Marilyn McMurchie, David A. Cooper

Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid mā Philip Cunningham, Danielle G. Smith, Claudette Satchell, David A. Cooper, Bruce J. Brew

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy mā Gilbert R. Kaufmann, Mark Bloch, Robert Finlayson, John Zaunders, Don Smith, David A. Cooper

Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells mā Chantelle Ahlenstiel, Heidi Lim, David A. Cooper, Takaomi Ishida, Anthony D. Kelleher, Kazuo Suzuki

Ngā utauta rapu:

Ngā marau whai pānga